- Datum04.04.2025
- Uhrzeit17:00 - 18:00 Uhr
- Veranstalter
XTB
Jens Klatt
Moderator
Spero Therapeutics Inc. Aktie
Verkaufen
Kaufen
Spero Therapeutics Inc. Chart
Spero Therapeutics Inc. Realtime-Kurs
| Name | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| L&S | VK | |||||
| Tradegate | VK | |||||
| Stuttgart | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
-11,61 %
Intraday
-18,59 %
1 Woche
-18,91 %
1 Monat
-39,42 %
Seit Jahresbeginn
-63,08 %
1 Jahr
-90,86 %
3 Jahre
-91,42 %
5 Jahre
-64,94 %
10 Jahre
Wikifolio
Passender Service zu Spero Therapeutics Inc.
Webinar zu Spero Therapeutics Inc.
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)0,624-1,800
- Jahrestief / Hoch ($)0,624-1,130
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Spero Therapeutics Inc.
Keine Dividenden verfügbar
Termine von Spero Therapeutics Inc.
Keine aktuellen Termine
Beschreibung
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
